Biocon Biologics Secures Landmark Deal to Launch Yesafili, a Breakthrough Biosimilar, in the US Market

Biocon Biologics has reached a landmark agreement with Regeneron to commercialize Yesafili, a biosimilar to Eylea, in the US by 2026, following FDA approval. This deal resolves leg...